Actavis and Forest Labs have agreed to sell or relinquish their rights to four generic pharmaceuticals to settle antitrust concerns stemming from their planned merger.
from WSJ.com: US Business http://ift.tt/1z3v5UW
via IFTTT
from WSJ.com: US Business http://ift.tt/1z3v5UW
via IFTTT
No comments:
Post a Comment